The Board of Directors and Nomination Committee have proposed the appointment of Anna Ljung as the new CEO of Moberg Pharma, while current CEO Peter Wolpert will transition to a
Nordic Life Science
NLS News
The company’s Board has appointed Axel Sjöblad as the new CEO starting June 17, 2019. Sjöblad most recently held the position as CEO of BioGaia and replaces Anki Malmborg Hager,
Emmanuel Dulac will join Zealand Pharma as new Chief Executive Officer on April 22, 2019. Emmanuel Dulac has 25 years of experience in the pharmaceutical industry, with a strong record
Mene Pangalos, EVP and President, Research & Development BioPharmaceuticals at AstraZeneca, was awarded the Prix Galien Award Greece on April 11, 2019. The Prix Galien Award is presented to individuals
We asked the new Minister about her goals and efforts when it comes to the country’s life science industry and Sweden’s status as an innovation and scientific research nation. How
The two companies have announced an expansion of their partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug
Sponsored Content
Drug & Device development
The first patient has been dosed in an additional cohort (“Cohort B”) of an ongoing phase II open-label study of BerGenBio’s selective AXL inhibitor bemcentinib in combination with Merck’s anti-PD-1 therapy KEYTRUDA
Together with LTS Lohmann Therapie-Systeme the company will start the first-ever clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019
A Phase II trial has demonstrated that Fasenra (benralizumab) can achieve near-complete depletion of eosinophils and improve clinical outcomes in hypereosinophilic syndrome (HES). In the randomized phase of the 20-patient trial, the
The company has initiated a novel TLR9 agonist project and announces a plan for a Phase I clinical trial. Clinical data shows that intratumoral delivery of TLR agonists in combination
The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019. ATOR-1017 is a monoclonal
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with CHI. “With the
The Board of Directors and Nomination Committee have proposed the appointment of Anna Ljung as the new CEO of Moberg Pharma, while current CEO Peter Wolpert will transition to a
Latest news
The first patient has been dosed in an additional cohort (“Cohort B”) of an ongoing phase II open-label study of BerGenBio’s selective AXL inhibitor bemcentinib in combination with Merck’s anti-PD-1 therapy KEYTRUDA
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
The first patient has been dosed in an additional cohort (“Cohort B”) of an ongoing phase II open-label study of BerGenBio’s selective AXL inhibitor bemcentinib in combination with Merck’s anti-PD-1 therapy KEYTRUDA
Together with LTS Lohmann Therapie-Systeme the company will start the first-ever clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019
A Phase II trial has demonstrated that Fasenra (benralizumab) can achieve near-complete depletion of eosinophils and improve clinical outcomes in hypereosinophilic syndrome (HES). In the randomized phase of the 20-patient trial, the
The company has initiated a novel TLR9 agonist project and announces a plan for a Phase I clinical trial. Clinical data shows that intratumoral delivery of TLR agonists in combination
The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019. ATOR-1017 is a monoclonal
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with CHI. “With the
The first patient has successfully been dosed in the company’s phase I study of ATOR-1015, its drug candidate in development for tumor-directed immunotherapy. ATOR-1015 is designed with properties that shall
The first cohort has been successfully dosed in the Phase 1, single ascending dose study to explore the pharmacokinetics and safety and tolerability of subcutaneous sevuparin injections in healthy volunteers
The latest research news from the Nordic region
Science Article
We asked the new Minister about her goals and efforts when it comes to the country’s life science industry and Sweden’s status as an innovation and scientific research nation. How
The European Parliament has voted to end daylight saving time in EU member states. The biannual clock changes will come to an end in 2021 when individual member states will
A Karolinska Institutet study on mice shows that the antibodies stabilise the plaque that accumulates on the artery walls, which reduces the risk of it rupturing and causing a blood
Even premature babies carry anti-viral antibodies transferred from the mother, researchers at Karolinska Institutet in Sweden report in a paper on maternal antibodies in newborns, published in the journal Nature Medicine.
Aishe A. Sarshad at the Sahlgrenska Academy, the University of Gothenburg, receives the L’Oréal-Unesco For Women in Science Prize in Sweden for having identified a new mechanism for regulating gene expression
We asked the new Swedish Minister for Higher Education and Research about what can be done to encourage and support women in science. Today is International Women’s Day and you